VOL. XCIV, NO. 247

★ MOAT STOCKS & COMPETITIVE ADVANTAGES ★

PRICE: 5 CENTS

Tuesday, December 23, 2025

Agilent Technologies, Inc.

A · New York Stock Exchange

active
Market cap (USD)$38.9B
SectorHealthcare
CountryUS
Data as of
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Request update

Spot something outdated? Send a quick note and source so we can refresh this profile.

Overview

Agilent Technologies, Inc. is a life-sciences tools company selling lab instruments, consumables, software and services. It reports three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets (GC/GCMS, spectroscopy and vacuum). Moats are mostly workflow switching costs in regulated labs, recurring consumables/parts pull-through from installed base, and a scaled global service/compliance footprint via CrossLab. Competitive risk remains high because key categories are oligopolies with strong incumbents and instrument demand is cyclical with customer capex. Market cap as of 2025-12-22: $38.85B (StockAnalysis.com).

Primary segment

Agilent CrossLab

Market structure

Competitive

Market share

HHI:

Coverage

3 segments · 6 tags

Updated 2025-12-22

Segments

Life Sciences and Diagnostics Markets

Life science and clinical lab analytical instruments, software and consumables (chromatography, mass spectrometry, pathology and genomics workflows)

Revenue

39.2%

Structure

Oligopoly

Pricing

moderate

Share

Peers

TMODHRWATBRKR+4

Agilent CrossLab

Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow

Revenue

41.9%

Structure

Competitive

Pricing

strong

Share

Peers

TMOAVTRDHRWAT

Applied Markets

Applied chemical analysis instruments (GC/GCMS, spectroscopy, vacuum) and related consumables for environmental, food, forensics, and industrial labs

Revenue

18.9%

Structure

Oligopoly

Pricing

moderate

Share

Peers

TMODHRWATBRKR+1

Moat Claims

Life Sciences and Diagnostics Markets

Life science and clinical lab analytical instruments, software and consumables (chromatography, mass spectrometry, pathology and genomics workflows)

FY25 net revenue $2,726M (39.2343% of total) and segment income from operations $536M (19.7% op margin). Derived from Agilent Q4 FY25 Financial Information (segment results) https://s24.q4cdn.com/305549747/files/doc_earnings/2025/q4/supplemental-info/Q4-25-Financial-Information-Final.pdf.

Oligopoly

Design In Qualification

Demand

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 3 evidence

Instrument platforms and software are embedded in regulated/validated lab workflows (QA/QC, method validation). Switching often requires revalidation, retraining and downtime planning.

Erosion risks

  • Customers adopt multi-vendor standardized methods and data formats
  • Performance parity and aggressive pricing from major rivals
  • Capex cycles shift toward lower-cost alternatives or leasing

Leading indicators

  • LC/LCMS installed-base share trend vs peers
  • Gross margin trend and discounting intensity
  • Win/loss rates in top pharma and clinical accounts

Counterarguments

  • Large labs periodically re-qualify alternative vendors during planned validation cycles
  • Third-party integration layers reduce dependence on any single OEM

Installed Base Consumables

Demand

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 1 evidence

Recurring pull-through from consumables and parts (e.g., chromatography columns, sample prep, standards, replacement parts) tied to the installed instrument base and workflow.

Erosion risks

  • Third-party compatible columns and parts take share on price
  • Customer standardization on generic consumables
  • Budget pressure drives mix to lower-margin supplies

Leading indicators

  • Consumables revenue growth vs instrument revenue growth
  • Attach-rate and reorder frequency in top platforms
  • Distributor/e-commerce mix shift

Counterarguments

  • Many consumables are compatible across vendors and compete heavily on price
  • Labs may source standardized consumables via distributors to reduce vendor dependence

Brand Trust

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

B2B reputation for reliability and support quality helps in regulated and mission-critical lab environments, but competition is intense and performance gaps can narrow.

Erosion risks

  • Competitors match support quality and reliability
  • Customers prioritize price over performance in downcycles

Leading indicators

  • Customer satisfaction/NPS disclosures and service renewal rates
  • Warranty and field-failure rate trends
  • Share shifts in core instrument categories

Counterarguments

  • Purchasing committees can treat instruments as comparable and negotiate aggressively
  • Brand advantages can weaken if product quality issues emerge

Agilent CrossLab

Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow

FY25 net revenue $2,908M (41.8538% of total) and segment income from operations $946M (32.5% op margin). Derived from Agilent Q4 FY25 Financial Information (segment results) https://s24.q4cdn.com/305549747/files/doc_earnings/2025/q4/supplemental-info/Q4-25-Financial-Information-Final.pdf.

Competitive

Service Field Network

Supply

Strength: 4/5 · Durability: durable · Confidence: 4/5 · 2 evidence

Service contracts, preventative maintenance and compliance services benefit from scale and proximity to a large installed base; OEM service reduces downtime risk for regulated labs.

Erosion risks

  • Third-party service providers undercut OEM pricing
  • Customers insource maintenance or extend replacement cycles
  • Remote diagnostics reduces need for dense field network

Leading indicators

  • Service contract renewal rate and attach rate
  • CrossLab operating margin trend
  • Backlog and services revenue growth vs installed base growth

Counterarguments

  • Independent service organizations can service many instruments at lower cost
  • Customers may accept longer downtime to reduce service spend

Data Workflow Lockin

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 2 evidence

Lab informatics (instrument control, data capture/analysis, compliant data storage) becomes embedded in SOPs, integrations and audit trails - raising switching and retraining costs.

Erosion risks

  • Customers standardize on vendor-neutral LIMS/ELN layers
  • Open formats/APIs reduce switching friction
  • Cybersecurity or data-integrity incidents weaken trust

Leading indicators

  • Informatics subscription/ARR disclosures (if provided)
  • Churn/renewal commentary on software offerings
  • Growth of integrations/partners on the platform

Counterarguments

  • Many labs prefer independent LIMS/ELN vendors as the system of record
  • Procurement can treat instrument software as replaceable if data export is robust

Installed Base Consumables

Demand

Strength: 4/5 · Durability: durable · Confidence: 3/5 · 1 evidence

Broad chemistries, supplies and lab automation consumables attach to recurring lab spend; CrossLab also benefits from parts and supplies tied to the instrument installed base.

Erosion risks

  • Distributor/private-label competition compresses margins
  • Customers consolidate spend with full-line distributors
  • Consumables shift to standardized/generic alternatives

Leading indicators

  • CrossLab revenue mix (consumables vs services vs software) if disclosed
  • Gross margin trend and price/mix commentary
  • Share in key consumables categories (e.g., columns) via third-party data

Counterarguments

  • Many consumables are readily substitutable and priced competitively
  • Large customers can force vendor-neutral supply contracts

Applied Markets

Applied chemical analysis instruments (GC/GCMS, spectroscopy, vacuum) and related consumables for environmental, food, forensics, and industrial labs

FY25 net revenue $1,314M (18.9119% of total) and segment income from operations $301M (22.9% op margin). Derived from Agilent Q4 FY25 Financial Information (segment results) https://s24.q4cdn.com/305549747/files/doc_earnings/2025/q4/supplemental-info/Q4-25-Financial-Information-Final.pdf.

Oligopoly

Installed Base Consumables

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 3 evidence

Installed base in GC/GCMS, spectroscopy and vacuum drives recurring demand for columns, parts, and other workflow consumables; however, compatibility and price competition are meaningful.

Erosion risks

  • Third-party consumables compatible with installed instruments
  • Government/industrial budgets drive price-focused procurement
  • Technology shifts reduce demand for certain legacy methods

Leading indicators

  • Aftermarket growth relative to instrument shipments
  • Pricing/mix commentary in applied markets
  • Share trends in GC/GCMS vs key peers

Counterarguments

  • Many applied-market labs optimize for total cost and can switch consumable brands easily
  • Alternative analytical techniques can displace some workflows over time

Brand Trust

Demand

Strength: 3/5 · Durability: medium · Confidence: 3/5 · 1 evidence

Reliability and applications support matter for regulated environmental/food labs, but the market is mature and price competition is persistent.

Erosion risks

  • Competitors match performance and service levels
  • Purchasers prioritize upfront price during budget stress

Leading indicators

  • Warranty/service incident rates
  • Win rate in government/environmental tenders
  • Gross margin trend in Applied Markets

Counterarguments

  • Products can be considered interchangeable for standardized methods
  • Brand premium is limited in commoditized product lines

Evidence

sec_filing
Agilent FY2024 Form 10-K (business description)

Describes OpenLab software enabling compliant instrument use in pharmaceutical QA/QC environments (supports inference of validation-driven switching costs).

sec_filing
Agilent Form 10-Q (Quarter ended Jan 31, 2025) - New Segment Structure

States LC and LC/MS platforms are part of the Life Sciences and Diagnostics Markets segment after the Nov 2024 reorganization.

other
Agilent Q4 FY25 Financial Information - Life Sciences and Diagnostics Markets segment results

Provides FY25 segment revenue ($2,726M) and segment operating margin (~19.7%) used to contextualize pricing power.

sec_filing
Agilent FY2024 Form 10-K (Chemistries and Supplies description)

Details consumables/supplies portfolio, including self-manufactured GC/LC columns, chemical standards and instrument replacement parts (supports consumables pull-through).

sec_filing
Agilent FY2024 Form 10-K (competition factors)

Lists competition based on reliability, support quality, applications expertise and global channel coverage - factors consistent with brand and trust advantages.

Showing 5 of 14 sources.

Risks & Indicators

Erosion risks

  • Customers adopt multi-vendor standardized methods and data formats
  • Performance parity and aggressive pricing from major rivals
  • Capex cycles shift toward lower-cost alternatives or leasing
  • Third-party compatible columns and parts take share on price
  • Customer standardization on generic consumables
  • Budget pressure drives mix to lower-margin supplies

Leading indicators

  • LC/LCMS installed-base share trend vs peers
  • Gross margin trend and discounting intensity
  • Win/loss rates in top pharma and clinical accounts
  • Consumables revenue growth vs instrument revenue growth
  • Attach-rate and reorder frequency in top platforms
  • Distributor/e-commerce mix shift
Created 2025-12-22
Updated 2025-12-22

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.